106 results on '"Cedrés S"'
Search Results
2. SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)
3. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients
4. DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
5. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
6. Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma
7. How to integrate current knowledge in selecting patients for first line in NSCLC?
8. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer
9. Fortalecimiento de las estrategias de transferencia para reducir las brechas de rendimientos en el sector arrocero
10. Adjuvant chemotherapy in non-small cell lung cancer (NSCLC)
11. MA04.07 Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection
12. LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial
13. 1733P Analysis of chemotherapy (Ct) efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)
14. 198P Analysis of efficacy of immunotherapy according to histology in malignant pleural mesothelioma (MPM) patients
15. 127P Real-world evidence and clinical characteristics in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI)
16. 126P Clinical predictive factors in real world setting in advanced non-small cell lung cancer (NSCLC) patients (pts)treated with immune checkpoint inhibitors (ICI)
17. P24.07 Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study)
18. P24.06 Real World use of Cisplatin and Carboplatin Based Therapy in Patients with Malignant Pleural Mesothelioma (MPM)
19. Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75]
20. 1807P Real world data on 442 patients (p) with small cell lung cancer (SCLC) treated in the last ten years at Vall d’Hebron Hospital
21. 1798P Carboplatin-paclitaxel (CP) chemotheraphy as salvage treatment for small cell lung cancer (SCLC): A real-world evidence analysis
22. 1910P Outcomes of systemic therapy after first line therapy in patients (p) with malignant pleural mesothelioma (MPM)
23. 572P Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials
24. Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient
25. 1989P - WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients
26. 1853P - Real-world use of systemic therapy in elderly patients with malignant pleural mesothelioma (MPM)
27. P2.06-01 STELLAR Trial: Radiological Response Patterns of TTFields Plus Chemotherapy in First-Line Treatment of Malignant Pleural Mesothelioma
28. P1.16-05 Incidence and Outcome of Multiple Primary Cancers (MPC) in a Series of Lung Cancer (LC) Patients
29. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches
30. Tumor Treating Fields plus chemotherapy for first-line treatment of malignant pleural mesothelioma: Final Results of the STELLAR Trial
31. 1807P - STELLAR: Final results of a phase II trial of TTFields with chemotherapy for first-line treatment of pleural mesothelioma
32. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)
33. 294 Erectile dysfunction associates own "arterial phenotype” defined by greater atherosclerotic burden, arterial stiffness and thickness and vascular reactivity lower than expected from exposure to risk factors
34. Rectal Metastases from Squamous Cell Carcinoma: A Case Report and Review of the Literature
35. P1.05-015 Major Pathological Response as a Predictive Value of Survival in Early-Stage NSCLC After Chemotherapy: Cohort of NATCH Phase III Trial
36. 1620P - Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated with immune-oncology drugs (IO) in clinical trials
37. 1278PD - Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial
38. 106P - Brain metastases (BM) development in molecular selected non-small cell lung cancer (NSCLC) patients included in clinical trials
39. 1272P - Analysis of outcomes and brain metastases (BM) of molecular selected non-small cell lung cancer (NSCLC) patients included in clinical trials
40. 1271P - KRAS mutations(m) in lung adenocarcinoma (AC) patients(p) receiving standard chemotherapy (ch) and immune checkpoint inhibitors (i-CI): Impact of KRAS clonality and coexisting TP53m
41. Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma
42. Analysis of expression of PTEN/PI3 K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
43. Exploratory analysis of activation of PTEN–PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM)
44. Rare tumours of the chest
45. 1556O_PR - Analysis of Expression of Programmed Cell Death 1 Ligand 1 (Pd-L1) in Malignant Pleural Mesothelioma (Mpm)
46. A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
47. Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non-Small-Cell Lung Cancer (NSCLC)
48. T05-O-04 Association between erectile dysfunction and coronary artery disease
49. Dynamic changes in circulating tumor <scp>DNA</scp> assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in <scp>NSCLC</scp>
50. Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.